Table 4. CDUS-R groupa .
| Variables | No DVT (n = 27) | DVT detected (n = 8) | p Value |
|---|---|---|---|
| Age (y)a | 39 ± 1.4 (34.8–43.7) | 53 ± 1.3 (44.3–63.7) | 0.011 |
| Gender | 0.433 | ||
| Female | 18 (66.7) | 4 (50.0) | |
| Male | 9 (33.3) | 4 (50.0) | |
| BMI (kg/m2)a | 25 ± 7.3 (23.7–27.4) | 23 ± 9.9 (19.2–26.1) | 0.159 |
| Fracture | 0.820 | ||
| Foot | 15 (55.6) | 4 (50.0) | |
| Ankle | 10 (37.0) | 4 (50.0) | |
| Ankle + foot | 2 (7.4) | 0 | |
| Ipsilateral | 25 (92.6) | 7 (87.5) | 0.553 |
| Bilateral | 2 (7.4) | 1 (12.5) | |
| Immobilization | 0.898 | ||
| Full cast | 3 (11.1) | 2 (25.0) | |
| Backslab | 2 (7.4) | 0 | |
| CAMboot | 19 (70.4) | 6 (75.0) | |
| Pressure bandage | 2 (7.4) | 0 | |
| None | 1 (3.7) | 0 | |
| Weight-bearing status | 1.000 | ||
| NWB | 11 (40.7) | 3 (37.5) | |
| PWB | 6 (22.2) | 2 (25.0) | |
| WBAT | 10 (37.0) | 3 (37.5) | |
| DVT symptoms | 0.006 | ||
| None | 26 (96.3) | 4 (50.0) | |
| Calf pain | 1 (3.7) | 4 (50.0) | |
| Time to fracture clinic (d)b | 28 ± 2.1 (21.3–36.5) | 29 ± 2.0 (17.5–47.1) | 0.871 |
| Time to CDUS (d)b | 28 ± 2.1 (20.8–36.7) | 29 ± 2.0 (17.4–45.7) | 0.905 |
| Smoking status | 0.597 | ||
| Nonsmoker | 9 (33.3) | 2 (25.0) | |
| Exsmoker | 11 (40.7) | 2 (25.0) | |
| Current | 7 (25.9) | 4 (50.0) | |
| History of current OCP use b | 1/18 (5.6) | 4/4 (100.0) | 1.000 |
| History of current HRT use b | 3/18 (16.7) | 2/5 (50.0) | 0.210 |
| Family history of VTE | 0 | 1 (12.5) | 0.229 |
Abbreviations: BMI, body mass index; CAMboot, controlled ankle movement boot; CDUS-R, compression duplex ultrasonography received; CDUS, compression duplex ultrasonography; DVT, deep vein thrombosis; HRT, hormone replacement therapy; NWB, nonweight bearing; OCP, oral contraceptive pill; PWB, partial weight bearing; VTE, venous thromboembolism; WBAT, weight bearing as tolerated.
a
n = 35.
b
Conversion from Log10 transformed data.
c
Comparison between female patients with no DVT (n = 18) and with DVT (n = 4).
Note: Data expressed as means ± SD (95% CI) or number (percentage). No patients had active cancer of history of clotting/bleeding disorders. Bold value highlights the only significant risk factor found in this study.